ConductScience.org, home

Paper19101136

In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with a quartz crystal microbalance.

Tan L and 6 others. Biosens Bioelectron, 2009. Cited by 74 papers, by iCite.

Cite this record

ConductScience Library. In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with a quartz crystal microbalance. Papers, record 19101136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/19101136

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
In vitro study on the individual and synergistic cytotoxicity of adriamycin and selenium nanoparticles against Bel7402 cells with a quartz crystal microbalance.
PubMed
Journal
Biosens Bioelectron
PubMed
Year
2009
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
74
iCite
Relative citation ratio, by iCite
2.38
iCite
Revised in PubMed
2013-11-21
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tan LLiang
2Jia XXue'en
3Jiang XXiangfu
4Zhang YYouyu
5Tang HHao
6Yao SShouzhuo
7Xie QQingji

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
ApoptosisMajor topic
DoxorubicinMajor topic
Liver NeoplasmsMajor topic
Micro-Electrical-Mechanical SystemsMajor topic
SeleniumMajor topic
Cell Line, Tumor
Drug Synergism
Humans
Nanoparticles
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 74 citations.

PMIDTitleJournalYearIn PapersSource
41214729Advances in biomedical applications of Se-based nanozymes.J Nanobiotechnology2025https://conductscience.org/library/papers/41214729PubMed
40765417Advances in selenium-based nanomedicines for cardiovascular disease therapy: mechanisms, current trends, and prospects.Nanomedicine (Lond)2025https://conductscience.org/library/papers/40765417PubMed
40138104Targets and Potential Mechanism of Chondroitin Sulfate A-selenium Nanoparticle on Kashin-Beck Disease Chondrocytes.Biol Trace Elem Res2025https://conductscience.org/library/papers/40138104PubMed
39875778Selenium-Enriched Lactiplantibacillus plantarum ZZU 8-12 Regulates Intestinal Microbiota and Inhibits Acute Liver Injury.Probiotics Antimicrob Proteins2025https://conductscience.org/library/papers/39875778PubMed
38796570Recent advances in the therapeutic applications of selenium nanoparticles.Mol Biol Rep2024https://conductscience.org/library/papers/38796570PubMed
38584179Species selective concentration and determination of nano-selenium and inorganic selenium species in environmental waters by micropore membrane filtration and ICP-MS.Anal Bioanal Chem2024https://conductscience.org/library/papers/38584179PubMed
38398553Selenium Nanoparticles: A Comprehensive Examination of Synthesis Techniques and Their Diverse Applications in Medical Research and Toxicology Studies.Molecules2024https://conductscience.org/library/papers/38398553PubMed
37445628Combinations of PRI-724 Wnt/β-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells.Int J Mol Sci2023https://conductscience.org/library/papers/37445628PubMed
36935493Theranostic applications of selenium nanomedicines against lung cancer.J Nanobiotechnology2023https://conductscience.org/library/papers/36935493PubMed
36819694Trends and recent progresses of selenium nanoparticles as novel autophagy regulators for therapeutic development.Front Nutr2023https://conductscience.org/library/papers/36819694PubMed
35300372Synthesis of silymarin-selenium nanoparticle conjugate and examination of its biological activity in vitro.ADMET DMPK2021https://conductscience.org/library/papers/35300372PubMed
33849555Selenium nanoparticles produce a beneficial effect in psoriasis by reducing epidermal hyperproliferation and inflammation.J Nanobiotechnology2021https://conductscience.org/library/papers/33849555PubMed
28991962Redox-active nanomaterials for nanomedicine applications.Nanoscale2017https://conductscience.org/library/papers/28991962PubMed
26229727
Epirubicin-[Anti-HER2/neu] Synthesized with an Epirubicin-(C13-imino)-EMCS Analog: Anti-Neoplastic Activity against Chemotherapeutic-Resistant SKBr-3 Mammary Carcinoma in Combination with Organic Selenium.
J Cancer Ther2011https://conductscience.org/library/papers/26229727PubMed
26005349Anticancer activity of biostabilized selenium nanorods synthesized by Streptomyces bikiniensis strain Ess_amA-1.Int J Nanomedicine2015https://conductscience.org/library/papers/26005349PubMed
25821636Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine.J Cancer Ther2015https://conductscience.org/library/papers/25821636PubMed
25692115Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7.Ann Surg Treat Res2015https://conductscience.org/library/papers/25692115PubMed
25322894Recovery of adriamycin induced mitochondrial dysfunction in liver by selenium.Cytotechnology2015https://conductscience.org/library/papers/25322894PubMed
23055734Co-nanoencapsulation of magnetic nanoparticles and selol for breast tumor treatment: in vitro evaluation of cytotoxicity and magnetohyperthermia efficacy.Int J Nanomedicine2012https://conductscience.org/library/papers/23055734PubMed
21997385Acoustic sensors as a biophysical tool for probing cell attachment and cell/surface interactions.Cell Mol Life Sci2012https://conductscience.org/library/papers/21997385PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/19101136

GET https://conductscience.org/api/papers/v1/19101136/authors